Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 2/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | G6PD | P11413 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8041685 | 0.90 | ALDH1A1 (0.58) | RAB9ASMN1; SMN2KCNMA1MEN1KMT2A | |
| SCHEMBL21423113 | 0.88 | RAB9A (0.53) | RAB9ASMN1; SMN2KCNMA1MEN1KMT2A | |
| SCHEMBL10223919 | 0.82 | KCNMA1 (0.62) | RAB9ASMN1; SMN2KCNMA1MEN1KMT2A | |
| SCHEMBL8054226 | 0.82 | CRHBP (0.58) | RAB9ASMN1; SMN2KCNMA1MEN1KMT2A | |
| SCHEMBL8055970 | 0.81 | KCNMA1 (0.64) | KCNMA1MEN1KMT2AALDH1A1HTT | |
| SCHEMBL8053243 | 0.80 | KCNMA1 (0.68) | RAB9ASMN1; SMN2KCNMA1MEN1KMT2A | |
| SCHEMBL8216235 | 0.79 | ALDH1A1 (0.47) | RAB9ASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL641132 | 0.78 | PHGDH (0.67) | RAB9AKCNMA1MEN1KMT2AALDH1A1 | |
| SCHEMBL8058441 | 0.78 | MAPT (0.56) | RAB9AMEN1KMT2AALDH1A1HTT | |
| SCHEMBL8041652 | 0.77 | KCNMA1 (0.52) | RAB9AKCNMA1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20210401784-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE | FIRST WAVE BIO, INC. | 2021-12-30 | — | — | US | disclosed |
| US-10912746-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10905666-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10849867-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10799468-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200276140-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-09-03 | — | — | US | disclosed |
| US-20200268694-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-08-27 | — | — | US | disclosed |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2017-03-02 | — | — | US | disclosed |
| US-8148328-B2 | Salicylanilides enhance oral delivery of therapeutic peptides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148328-B2 | Salicylanilides enhance oral delivery of therapeutic peptides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110183889-A1 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110183889-A1 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-07-28 | — | — | US | disclosed |
| US-20090163408-A1 | SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163408-A1 | SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-06-25 | — | — | US | disclosed |
| WO-2009032749-A2 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNINA (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401784-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE | FH, CS, ECHS1 | RAB9A 2223/4885SMN1; SMN2 1157/4885KCNMA1 1478/4885 |
| US-20200268694-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | RAB9A 2177/4885SMN1; SMN2 1106/4885KCNMA1 1417/4885 |
| US-20090163408-A1 | SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES | DNPEP, NGLY1, VIP | RAB9A 2567/4885SMN1; SMN2 1342/4885KCNMA1 4565/4885 |
| US-10849867-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | RAB9A 2223/4885SMN1; SMN2 1157/4885KCNMA1 1478/4885 |
| US-10799468-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | RAB9A 2177/4885SMN1; SMN2 1106/4885KCNMA1 1417/4885 |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | RAB9A 2177/4885SMN1; SMN2 1106/4885KCNMA1 1417/4885 |
| US-10912746-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | RAB9A 2227/4885SMN1; SMN2 1088/4885KCNMA1 1490/4885 |
| US-20110183889-A1 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | DNPEP, PTMS, NGLY1 | RAB9A 2829/4885SMN1; SMN2 1291/4885KCNMA1 3753/4885 |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | RAB9A 2177/4885SMN1; SMN2 1106/4885KCNMA1 1417/4885 |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | RAB9A 2177/4885SMN1; SMN2 1106/4885KCNMA1 1417/4885 |
| US-20200276140-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | RAB9A 2177/4885SMN1; SMN2 1106/4885KCNMA1 1417/4885 |
| US-10905666-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | RAB9A 2223/4885SMN1; SMN2 1157/4885KCNMA1 1478/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | RAB9A 2223/4885SMN1; SMN2 1157/4885KCNMA1 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.